|
|
|
|
| Join this Outsourced Pharma Live discussion: Charting a Direct Pathway from Academia To CDMOs on August 4, 2026 to learn how academic innovators, technology transfer offices, and CDMOs can bridge critical gaps in documentation, quality expectations, and development strategy. Hear practical advice on creating stronger technical packages, aligning earlier with CDMO partners, and accelerating the path from promising research to real-world manufacturing success. Register. |
|
|
|
|
|
| De-Risking FIH: Integrated Strategies For Rapid Proof-Of-Concept | Article | By Andreas Reichl, M.D., and Kevin Schaab, Ph.D., Quotient Sciences | Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept. |
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | What separates high-performing sponsor-CDMO partnerships from struggling ones? Velocity. With 30+ years of experience, Ratna Shekhar is focused on how real speed drives results. Chief Editor Louis Garguilo investigates. | |
|
|
Overcoming The Hidden Pitfalls Of MES Selection | By Andreas Grossman, Christian Berg, Ciera Clayton, Emilee Cook, Ines Kaci, Katherine Farley, Kim Wilson, Kortney Gunther, and Mooch Agirtmis, members of BioPhorum | Many manufacturing execution system requests for proposals fail. Not because vendors cannot deliver or the tech is immature, but because the requirements are written backward. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
